DUBLIN, Sept. 1, 2016
/PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today
announced it has received tentative approval from the U.S. Food and
Drug Administration for the generic version of Epiduo® Gel
(adapalene and benzoyl peroxide 0.1%/2.5%).
Epiduo® Gel (adapalene and benzoyl peroxide 0.1%/2.5%) is
indicated for the treatment of acne vulgaris in patients 12 years
of age and older. Annual sales for the 12 months ending
July 2016 were $379 million.
Perrigo's CEO John T. Hendrickson
stated, "This tentative approval is another example of Perrigo's
ongoing commitment to developing high quality value alternatives in
important treatment categories. The Rx team continues to leverage
Perrigo's development capabilities in order to deliver Quality
Affordable Healthcare Products® to our customers and
consumers around the world."
About Perrigo
Perrigo Company plc, a top five global over-the-counter ("OTC")
consumer goods and pharmaceutical company, offers patients and
customers high quality products at affordable prices. From its
beginnings in 1887 as a packager of generic home remedies, Perrigo,
headquartered in Ireland, has
grown to become the world's largest manufacturer of OTC products
and supplier of infant formulas for the store brand market. The
Company is also a leading provider of generic extended topical
prescription products and receives royalties from Multiple
Sclerosis drug Tysabri®. Perrigo provides Quality Affordable
Healthcare Products® across a wide variety of product categories
and geographies primarily in North
America, Europe, and
Australia, as well as other
markets, including Israel,
China and Latin America. Visit Perrigo online at
(http://www.perrigo.com).
Forward-Looking Statements
Certain statements in this press release are "forward-looking
statements." These statements relate to future events or the
Company's future financial performance and involve known and
unknown risks, uncertainties and other factors that may cause the
actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those
expressed or implied by any forward-looking statements. In some
cases, forward-looking statements can be identified by terminology
such as "may," "will," "could," "would," "should," "expect,"
"plan," "anticipate," "intend," "believe," "estimate," "predict,"
"potential" or the negative of those terms or other comparable
terminology. The Company has based these forward-looking statements
on its current expectations, assumptions, estimates and
projections. While the Company believes these expectations,
assumptions, estimates and projections are reasonable, such
forward-looking statements are only predictions and involve known
and unknown risks and uncertainties, many of which are beyond the
Company's control, including the timing, amount and cost of share
repurchases, future impairment charges, the ability to achieve its
guidance and the ability to execute and achieve the desired
benefits of announced initiatives. These and other important
factors, including those discussed under "Risk Factors" in the
Company's Form 10-KT for the six-month period ended December 31, 2015, as well as the Company's
subsequent filings with the SEC, may cause actual results,
performance or achievements to differ materially from those
expressed or implied by these forward-looking statements. The
forward-looking statements in this press release are made only as
of the date hereof, and unless otherwise required by applicable
securities laws, the Company disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Logo -
http://photos.prnewswire.com/prnh/20120301/DE62255LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/perrigo-announces-tentative-fda-approval-for-generic-version-of-epiduo-gel-300321435.html
SOURCE Perrigo Company plc